Compare StocksCVS vs GS

CVS Health Corporation (CVS) vs Goldman Sachs Group, Inc. (The) (GS): Which Is the Better Buy in 2026?

As of 2026-08-03, CVS is overvalued at $104, with a DCF intrinsic value of $29 and a margin of safety of -263%. GS is undervalued at $1018, with an intrinsic value of $481431875452 and a margin of safety of 100%. Of the two, GS has the wider margin of safety.

CVS
CVS Health Corporation
$104.43
VS
GS
Goldman Sachs Group, Inc. (The)
$1018.38

Rewards

CVS
  • Management has timed buybacks well — 2 out of 3 years showed value-accretive repurchases.
  • PEG ratio of 0.29 suggests the stock is undervalued relative to its growth rate — paying less than 1x for each unit of earnings growth.
GS
  • Gross margin of 82.1% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • Each dollar of retained earnings has created $2.58 of earning power — management is an exceptional capital allocator.

Risks

CVS
  • Gross margin of 13.4% is low, suggesting a competitive or commodity-like market with limited pricing power.
  • FCF yield of 5.9% suggests reasonable valuation assuming continued moderate growth.
  • Trailing P/E of 45.8x is 67% above the historical average of 27.4x — the stock trades at a premium to its own history.
GS
  • Altman Z-Score of 0.16 places the company in the distress zone — financial patterns resemble those of companies that experienced bankruptcy.
  • Insiders have sold $20.4M worth of stock in the past 3 months — significant insider liquidation.

Key Valuation Metrics

Learn more →
CVS
GS
Valuation
$7.81B
Free Cash Flow
N/A
5.86%
FCF Yield
N/A
45.80
Trailing P/E
15.72
12.40
Forward P/E
13.81
Quality & Moat
8.47%
ROIC
2.46%
3.75%
ROE
16.95%
13.39%
Gross Margin
82.08%
0.29
PEG Ratio
1.45
Balance Sheet Safety
0.86
Net Debt / Equity
Net cash
N/A
Interest Coverage
N/A
4.32
Net Debt / EBITDA
N/A
2.55%
Dividend Yield
1.96%
CVS: 4Ties: 1GS: 4
CVSGS

Historical Fundamentals

Learn more →
CVS

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

GS

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
CVS
$-4.20
created per $1 retained over 3 years
Market Cap Declined
Σ Retained
$4.82B
Δ Market Cap
$-20.28B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
GS
$0.00
created per $1 retained over 3 years
Value Destroyer
Σ Retained
$26.00B
Δ Market Cap
+$535.62
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
CVS
262.9% Overvalued
Price is 262.9% above estimated fair value
Current Price: $104.43
Fair Value: $28.78
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
GS
100.0% Margin of Safety
Price is 100.0% below estimated fair value
Current Price: $1018.38
Fair Value: $481431875452.18
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
CVS

What growth rate is the market pricing in at $104?

+21.9%
Market-Implied Owner Earnings Growth
Standard FCF implies +11.1%

The market implies +21.9% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +11.1%, reflecting heavy growth investment.

GS

Requires positive FCF to compute implied growth rate.

Economic Moat Score

Learn more →
CVS
49/100
Narrow Moat
70+ Wide · 40-69 Narrow · <40 None

Narrow moat with revenue predictability as the key competitive advantage. Improving roic consistency would strengthen the moat.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
GS
65/100
Narrow Moat
70+ Wide · 40-69 Narrow · <40 None

Narrow moat with reinvestment efficiency as the key competitive advantage. Improving margin stability would strengthen the moat.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

Forensic Accounting

Learn more →
CVS
-2.54
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
GS
-2.00
Possible Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
CVS
Insiders 0.1%Institutions 90.3%Retail & Other 9.6%
No. of Institutional Holders2,546
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
GS
Insiders 0.5%Institutions 74.8%Retail & Other 24.7%
No. of Institutional Holders3,873
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
CVS
0
Buys (3M)
0
Buys (12M)
SANSONE GUY P
Director
$100,009
@ $63.70 · 2025-06-05
MAHONEY MICHAEL F
Director
$2.00M
@ $66.70 · 2025-02-18
NELSON STEVEN H
Officer
$1,289
@ $53.71 · 2025-01-23
CAPOZZI HEIDI B
Officer
$4,589
@ $57.36 · 2024-10-23
Open market purchases · includes direct & indirect ownership · excludes option exercises
GS
0
Buys (3M)
0
Buys (12M)
HESS JOHN B JR.
Director
$2.00M
@ $511.68 · 2025-04-15
JOHNSON KEVIN RONALD
Director
$1.49M
@ $619.02 · 2025-01-17
FLAHERTY MARK A
Director
$29,545
@ $360.30 · 2024-09-27
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
CVS
1
Sells (3M)
1
Sells (12M)
Total value (12M): $6.23M
MANDADI TILAK
Officer
$6.23M
@ $89.58 · 2026-05-08
CLARK JAMES DAVID
Officer
$498,488
@ $66.35 · 2025-03-05
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
GS
3
Sells (3M)
15
Sells (12M)
Total value (12M): $78.42M
LESLIE ERICKA T
Officer
$287,951
@ $1151.80 · 2026-07-15
COLEMAN DENIS P.
Chief Financial Officer
$6.68M
@ $973.55 · 2026-05-14
RUEMMLER KATHRYN H
General Counsel
$13.42M
@ $939.07 · 2026-05-06
RUEMMLER KATHRYN H
General Counsel
$634,927
@ $929.61 · 2026-05-01
FREDMAN SHEARA J.
Officer
$9.57M
@ $929.17 · 2026-05-01
SOLOMON DAVID M
Chief Executive Officer
$3.23M
@ $930.70 · 2026-05-01
GOLTEN ALEXANDER SIMON
Officer
$1.04M
@ $936.18 · 2026-04-23
GOLTEN ALEXANDER SIMON
Officer
$1.02M
@ $919.19 · 2026-04-17
COLEMAN DENIS P.
Chief Financial Officer
$10.94M
@ $941.57 · 2026-02-09
SOLOMON DAVID M
Chief Executive Officer
$255,387
@ $938.92 · 2026-01-29
HALIO CAREY
Officer
$2.64M
@ $927.17 · 2026-01-27
RUEMMLER KATHRYN H
General Counsel
$8.89M
@ $927.51 · 2026-01-23
HALIO CAREY
Officer
$1.62M
@ $920.62 · 2026-01-23
FREDMAN SHEARA J.
Officer
$4.49M
@ $923.75 · 2026-01-23
WALDRON JOHN E.
President
$13.69M
@ $750.30 · 2025-08-28
COLEMAN DENIS P.
Chief Financial Officer
$5.41M
@ $724.40 · 2025-07-25
ROGERS JOHN F W
Officer
$4.31M
@ $717.39 · 2025-07-23
SOLOMON DAVID M
Chief Executive Officer
$4.71M
@ $712.31 · 2025-07-23
SOLOMON DAVID M
Chief Executive Officer
$3.04M
@ $607.17 · 2025-05-14
SOLOMON DAVID M
Chief Executive Officer
$1.50M
@ $622.15 · 2025-02-26
GOLTEN ALEXANDER SIMON
Officer
$3.31M
@ $636.25 · 2025-01-28
HALIO CAREY
Officer and Treasurer
$2.32M
@ $636.74 · 2025-01-24
HALIO CAREY
Officer
$965,120
@ $624.67 · 2025-01-21
FREDMAN SHEARA J.
Officer
$1.28M
@ $627.01 · 2025-01-21
RUEMMLER KATHRYN H
General Counsel
$4.76M
@ $634.69 · 2025-01-21
SOLOMON DAVID M
Chief Executive Officer
$4.00M
@ $610.91 · 2024-11-29
VINIAR DAVID A
Director
$3.06M
@ $612.08 · 2024-11-29
ROGERS JOHN F W
Officer
$3.83M
@ $596.36 · 2024-11-06
COLEMAN DENIS P.
Chief Financial Officer
$7.67M
@ $593.03 · 2024-11-06
FREDMAN SHEARA J.
Officer
$1.77M
@ $594.51 · 2024-11-06
SOLOMON DAVID M
Chief Executive Officer
$3.00M
@ $500.29 · 2024-08-15
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
CVS
FearGreed
😏Greed(62/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
GS
FearGreed
😐Neutral(53/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
CVS
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (62)
GS
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (53)
View CVS Full AnalysisView GS Full Analysis

Frequently Asked Questions: CVS vs GS

Is CVS Health Corporation or Goldman Sachs Group, Inc. (The) more undervalued in 2026?

Based on our discounted cash flow model, GS trades at a 100.0% margin of safety (intrinsic value $481431875452 vs. price $1018), compared to CVS's -262.9% margin of safety (intrinsic $29 vs. $104).

Which stock has a wider economic moat, CVS Health Corporation or Goldman Sachs Group, Inc. (The)?

GS scores 65/100 (Narrow moat), while CVS scores 49/100 (Narrow moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is Goldman Sachs Group, Inc. (The) in financial distress?

GS's Altman Z-Score of 0.2 places it in the Distress zone, signaling elevated bankruptcy risk. CVS scores 2.3 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which stock has higher return on invested capital, CVS Health Corporation or Goldman Sachs Group, Inc. (The)?

CVS earns 8.5% ROIC versus GS's 2.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, CVS Health Corporation's or Goldman Sachs Group, Inc. (The)'s?

GS's dividend earns a safety score of 79/100 (Safe), compared to CVS's 45/100 (Borderline). GS has raised its dividend for 3 consecutive years.